Enrique Fernandez, MD
Neurology with Special Qualifications in Child Neurology · Brunswick, GANPI 1912978065
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 23.0%. 2025 is the largest year on record at $5,260, 8.7 times the $603 reported in 2019.
Across 224 payments — averaging $37.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Boston Scientific$1K
- Livanova USA, Inc.$993
- AbbVie$544
- Pfizer$340
- EMD Serono, Inc.$309
- plus $3K from 34 others
What the payments were for
- Speaking & faculty fees$170%
- Travel & lodging$3,55642%
- Food & beverage$4,67456%
- Education$1342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 15 | $1,927 |
| Boston Scientific | 6 | $1,449 |
| Livanova USA, Inc. | 4 | $993 |
| AbbVie(2 entities) | 27 | $544 |
| Pfizer | 21 | $340 |
| EMD Serono, Inc. | 17 | $309 |
| Biogen | 14 | $270 |
| MDD US Operations, LLC | 5 | $257 |
| Acadia Pharmaceuticals Inc | 10 | $197 |
| Teva Pharmaceuticals USA, Inc. | 5 | $188 |
| Eisai Inc. | 9 | $159 |
| Amgen | 7 | $125 |
| UCB, Inc. | 6 | $123 |
| AstraZeneca | 4 | $114 |
| Sumitomo Pharma America, Inc. | 6 | $106 |
| Adamas Pharmaceuticals, Inc. | 6 | $101 |
| Genentech USA, Inc. | 5 | $97 |
| Kyowa Kirin, Inc. | 5 | $94 |
| Grifols USA, LLC | 4 | $80 |
| TG Therapeutics, Inc. | 3 | $79 |
| Supernus Pharmaceuticals, Inc. | 5 | $78 |
| Novartis | 4 | $78 |
| Greenwich Biosciences, Inc. | 4 | $74 |
| Jazz Pharmaceuticals Inc. | 3 | $71 |
| SK Life Science, Inc. | 2 | $60 |
| Sunovion Pharmaceuticals Inc. | 7 | $59 |
| Argenx US, Inc. | 2 | $56 |
| Neurelis, Inc. | 3 | $52 |
| Amneal Pharmaceuticals LLC | 2 | $46 |
| CSL Behring | 2 | $43 |
| Lundbeck LLC | 2 | $37 |
| ANI Pharmaceuticals, Inc. | 1 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Cook Medical LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $19 |
| Immedica Pharma US, Inc. | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Acorda Therapeutics, Inc | 1 | $17 |
| Upsher-smith Laboratories LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERCISE$1,352
- VNS Therapy$979
- VISUALASE$780
- PERCEPT PC BRAINSENSE$599
- GOCOVRI$184
- Mavenclad$125
How this compares
$8,380 in reported general payments places this provider in the 75th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
See all neurology with special qualifications in child neurology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 31 | $377,067 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 13 | $354,215 |
| EpidiolexCannabidiol (Cbd) | 26 | $219,404 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 13 | $217,373 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 14 | $188,915 |
| Kesimpta PenOfatumumab | 17 | $186,477 |
| Rebif RebidoseInterferon Beta-1a/Albumin | 12 | $124,122 |
| FycompaPerampanel | 43 | $51,852 |
| Aimovig AutoinjectorErenumab-Aooe | 46 | $45,807 |
| Emgality PenGalcanezumab-Gnlm | 37 | $44,554 |
| NamzaricMemantine Hcl/Donepezil Hcl | 55 | $42,140 |
| Topiramate ErTopiramate | 33 | $28,607 |
| UbrelvyUbrogepant | 23 | $25,325 |
| Nurtec OdtRimegepant Sulfate | 16 | $20,161 |
| QuliptaAtogepant | 15 | $20,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt, Dilantin | $340 | $376,94542 claims |
| CSL BehringPrivigen | $43 | $188,91514 claims |
| AbbVieNamzaric, Ubrelvy, Qulipta | $544 | $87,58793 claims |
| Eisai Inc.Fycompa | $159 | $51,85243 claims |
| UCB, Inc.Vimpat | $123 | $16,71814 claims |
| SK Life Science, Inc.Xcopri | $60 | $11,35511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.
Other neurology with special qualifications in child neurology in Brunswick
- Sharlisa HutsonBrunswick$437
- John HemphillSavannah$2M
- Chaouki KhouryAtlanta$978K
- Katherine MoretzSavannah$144K
- Yong ParkAugusta$78K
- Daniel TarquinioGainesville$50K
- Han PhanAtlanta$44K
- Raymond ChengAtlanta$40K
- Sonam BhallaAtlanta$23K
- Cherise FrazierAtlanta$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.